학술논문
A prospective surveillance study in haemophilia B patients following a population switch to recombinant factor IX (nonacog gamma).
Document Type
Article
Author
Source
Subject
*HEMOPHILIA
*VON Willebrand disease
*LONGITUDINAL method
*
*
Language
ISSN
1351-8216
Abstract
The presence of anti-FIX antibodies has been previously detected by ELISA in HB patients that were negative by NBA.9 The first three subjects were positive only at visit 3, but competitive ELISA assays revealed that these antibodies were not specific to FIX. Haemophilia B (HB) is an inherited bleeding disorder caused by I F9 i mutations resulting in a deficiency in factor IX (FIX) activity. We conducted an observational surveillance study from March 2017 to January 2020 to compare different parameters before and after the switch: FIX consumption, annualized bleeding rates (ABRs), FIX recovery, inhibitors, activated partial thromboplastin time (APTT) and D-dimer levels. [Extracted from the article]